Cardiff Oncology, Inc. - Common Stock (CRDF)

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class
Equity / Common Stock
Shares outstanding
66,577,393
Total 13F shares
5,456,265
Share change
-535,723
Total reported value
$7,583,910
Put/Call ratio
28%
Price per share
$1.39
Number of holders
55
Value change
-$756,925
Number of buys
18
Number of sells
18

Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2023

As of 30 Sep 2023, Cardiff Oncology, Inc. - Common Stock (CRDF) was held by 55 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,456,265 shares. The largest 10 holders included VANGUARD GROUP INC, Laurion Capital Management LP, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, MAI Capital Management, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, BLAIR WILLIAM & CO/IL, Assenagon Asset Management S.A., and SUSQUEHANNA INTERNATIONAL GROUP, LLP. This page lists 55 institutional shareholders reporting positions in this security for the Q3 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.